British Patient Capital

Maxion Therapeutics specializes in developing innovative therapies through its drug discovery platform, which focuses on creating antibody-like therapeutics targeting ion channel and GPCR-driven diseases. The company utilizes unique ion channel-modulating mini-proteins, known as knottins, derived from venom and other sources, integrating them with antibody frameworks. This approach preserves the functional properties of knottins while enhancing the drug-like characteristics typical of antibodies. By doing so, Maxion Therapeutics aims to provide long-acting, safe, and effective treatments for conditions such as chronic pain, autoimmune disorders, and heart disease, addressing previously inaccessible therapeutic targets.

Quantexa Limited is a global data and analytics software company based in London, United Kingdom, specializing in Contextual Decision Intelligence. Incorporated in 2016, Quantexa develops advanced entity resolution and network analytics technology that empowers organizations to improve their operational decisions by unifying siloed data and generating a comprehensive view of internal and external information. Its platform leverages artificial intelligence to uncover hidden risks and opportunities, providing critical insights into the relationships between individuals, organizations, and locations. Quantexa's solutions address challenges in areas such as fraud prevention, anti-money laundering, compliance, and customer insights, serving clients across financial services, corporate sectors, and public organizations worldwide. The company has established a strategic alliance with Accenture to enhance its offerings and expand its market reach.

Cambridge GaN Devices specializes in the development and commercialization of gallium nitride (GaN) power devices aimed at improving energy efficiency in electronic applications. The company offers a variety of GaN-based semiconductor products that enhance power conversion and minimize energy loss across different systems. These advanced devices find applications in sectors such as renewable energy, electric vehicles, and consumer electronics, supporting the shift towards more sustainable technologies. Cambridge GaN Devices focuses on creating transistors that are faster, more compact, and more efficient than traditional silicon alternatives, thereby enabling industries to utilize tailored semiconductors for critical applications. The company collaborates with industry partners to promote innovation and facilitate the integration of its technology into the power semiconductor market.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

Tokamak Energy Ltd is a private company based in Abingdon, United Kingdom, focused on the development of fusion power technology. Established in 2009, it specializes in creating compact fusion reactors known as spherical tokamaks, which offer a more efficient means of achieving high plasma pressure compared to traditional designs. The company's key products, the ST25 and ST40, utilize high-temperature superconductors and advanced materials to enhance plasma confinement and overall reactor performance. By leveraging decades of scientific research, Tokamak Energy aims to accelerate the commercial viability of fusion energy, positioning itself as a leader in the pursuit of affordable and sustainable energy solutions that contribute to global energy security while minimizing environmental impact.

Purespring Therapeutics is an innovative company dedicated to developing gene therapies for kidney diseases, with a strong emphasis on podocytes, the specialized cells in the kidneys. As one of the pioneers in utilizing AAV gene therapy for renal conditions, Purespring aims to address significant unmet medical needs in this challenging area of healthcare. The company has established an in-vivo functional screening platform designed to identify protective factors that could be beneficial across a range of kidney diseases, while also exploring applications for gene therapy in cardiovascular disorders. Through its focused approach, Purespring is positioned to make a meaningful impact in the treatment of renal conditions.

Form3 is a London-based company that provides cloud-based payment processing, clearing, and settlement services tailored for regulated financial institutions. Established in 2016, it offers a fully managed payment technology service built on a robust AWS cloud processing platform. Form3's architecture includes multiple payment gateways and a micro-services framework, allowing clients to access a comprehensive range of payment schemes through a single application programming interface (API). This technology facilitates secure and reliable agency payment services on a per-transaction basis without upfront costs. Its clientele consists of various financial entities, including leading banks, non-bank financial institutions, and fintech companies, such as payment institutions and e-money providers.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Wagestream Ltd., founded in 2018 and headquartered in London, United Kingdom, develops a financial services application designed to enhance employee benefits and financial well-being. The platform allows employees to access their earned wages instantly, providing them with greater control over their pay schedules. This innovation aims to alleviate financial stress related to unexpected expenses by eliminating the need for advances, loans, and the burdens of high-interest credit or payday loans. Additionally, Wagestream offers various financial tools that help businesses support their employees in managing expenses, setting savings goals, and developing financial plans. By addressing these financial challenges, Wagestream seeks to reduce the poverty premium and prevent employees from falling into cycles of debt.

Phagenesis Limited is focused on developing medical device technology aimed at treating dysphagia, a condition that impairs swallowing, often resulting from strokes or brain injuries. The company's primary product, Phagenyx, consists of a base station that delivers electrical stimulations to the patient and records pertinent information, along with a catheter that is introduced through the nose to stimulate the pharynx. This innovative approach leverages the brain's ability to relearn lost functions through neuroplasticity, effectively aiding patients in regaining control over their swallowing mechanisms. Founded in 2007 and based in Manchester, United Kingdom, Phagenesis emphasizes research and evidence-based solutions, with foundational work led by Professor Shaheen Hamdy of the University of Manchester, whose findings have been published in prestigious medical journals.

Curve Therapeutics Limited is a drug-discovery company based in London, United Kingdom, founded in 2019. The company focuses on developing technologies to target currently undruggable disease-modifying targets, with a primary emphasis on cancer. Curve has created an innovative screening platform that allows for the functional screening of genetically encoded Microcycle™ libraries against a variety of disease-associated targets in their native conformation within mammalian cells. This platform is designed to facilitate the discovery of first-in-class therapeutics, enabling the development of a pipeline of novel cancer drugs. By targeting challenging cancer interactions, including intracellular protein-protein and protein-gene interactions, Curve Therapeutics aims to deliver advanced treatments for complex cancer-related conditions.

Tenpoint Therapeutics is a biotechnology company dedicated to developing engineered cell-based therapies aimed at restoring vision for individuals affected by degenerative ocular diseases. The company leverages an innovative platform that includes in vivo reprogramming techniques, allowing for targeted delivery of therapeutic systems directly to the eye. This approach eliminates the need for systemic administration, which can improve treatment efficacy and patient outcomes. By focusing on vision restoration, Tenpoint Therapeutics strives to significantly enhance the quality of life for patients suffering from various eye conditions.

OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.

Quantexa Limited is a global data and analytics software company based in London, United Kingdom, specializing in Contextual Decision Intelligence. Incorporated in 2016, Quantexa develops advanced entity resolution and network analytics technology that empowers organizations to improve their operational decisions by unifying siloed data and generating a comprehensive view of internal and external information. Its platform leverages artificial intelligence to uncover hidden risks and opportunities, providing critical insights into the relationships between individuals, organizations, and locations. Quantexa's solutions address challenges in areas such as fraud prevention, anti-money laundering, compliance, and customer insights, serving clients across financial services, corporate sectors, and public organizations worldwide. The company has established a strategic alliance with Accenture to enhance its offerings and expand its market reach.

CyberSmart Ltd. is a London-based company that specializes in designing and developing automated compliance software. Founded in 2016, the company offers a range of products including Cyber Essentials, Cyber Essentials Plus, GDPR Ready, and its flagship CyberSmart platform. This platform assists small to medium-sized businesses in identifying, addressing, certifying, and safeguarding against security incidents. Key features include the CE Smart tool, which identifies and certifies security incidents, and a cloud-based dashboard that manages compliance processes. Additionally, CyberSmart provides ongoing protection through regular security checks and cyber insurance coverage, ensuring that businesses can navigate the complexities of cybersecurity and regulatory compliance in a rapidly evolving digital landscape.

Quantum Motion Technologies is focused on developing universal quantum computers utilizing silicon-based, CMOS-compatible processes. The company aims to address key challenges in quantum computing, such as fault tolerance and qubit redundancy, by creating scalable architectural technologies. By leveraging complementary metal-oxide semiconductor processing, Quantum Motion strives to achieve greater qubit density, enabling the construction of large-scale quantum systems. This approach not only enhances the performance of quantum computers but also assists clients in the quantum technology sector in overcoming significant errors and critical challenges in quantum information processing.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Perspectum is a global medical technology company that focuses on improving care for patients with liver disease, diabetes, and cancer. By utilizing advanced imaging and genetics, the company emphasizes precision medicine to enhance early detection, diagnosis, and targeted treatment of complex health issues. Perspectum's diverse team, which includes physicians, biomedical scientists, engineers, and technologists, works collaboratively to develop innovative digital technologies. Their aim is to empower both patients and clinicians by providing quantitative health assessments, enabling more effective management of metabolic diseases and multi-organ pathology.

PragmatIC specializes in ultra-low-cost flexible electronics, specifically through the development of flexible integrated circuits (FlexICs) that are thinner than human hair. These circuits can be invisibly embedded in various objects, allowing for innovative solutions to everyday challenges that traditional electronics cannot address effectively. The company offers a FlexIC Foundry service, enabling designers to create application-specific flexible devices at a reduced cost and time compared to conventional silicon circuits, thus opening new market opportunities. Additionally, PragmatIC provides standard FlexIC products that enhance established technologies like RFID and NFC for mass-market applications, paving the way for a vast array of smart objects capable of interacting with consumers and their environments. FlexICs are produced using the company's unique FlexLogIC production system, which allows for cost-effective, high-volume manufacturing with significantly lower capital and operational costs than traditional silicon fabrication. Headquartered in Cambridge, UK, PragmatIC serves a diverse range of industries, including consumer goods, retail, healthcare, and security, with a growing global clientele.

Nucleome Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on transforming drug discovery by decoding the complexities of the human genome. Founded in 2019, the company utilizes a unique genomics platform that leverages the three-dimensional structure of the genome and machine learning to explore the vast, largely uncharted regions of the genome, often referred to as the dark matter. This area contains over 95% of disease-linked genetic variants, providing significant opportunities for identifying new therapeutic targets. Nucleome Therapeutics specializes in creating high-resolution genome structure maps and validating genetic variants in primary cell types, facilitating the discovery and development of novel precision medicines. The company's initial emphasis is on lymphocytes and autoimmune diseases, with the goal of establishing a robust pipeline of drug candidates and corresponding biomarkers. Founded by experts in gene regulation from the University of Oxford, Nucleome is backed by investments from Oxford Sciences Innovation.

Oxford Quantum Circuits specializes in quantum computing technology that aims to address significant global challenges, such as climate change and drug discovery. The company has developed a fully functional quantum computer that integrates control systems, hardware, and software, enabling customers to streamline operations and explore innovative solutions. Their unique superconducting circuits are designed to maintain high qubit quality and control, which is essential for achieving commercially viable processing power. By leveraging this advanced technology, Oxford Quantum Circuits supports a range of applications, from pioneering new battery technologies to facilitating life-changing discoveries in medicine.

CloudNC Ltd. is a London-based company that specializes in developing software to automate the programming of computerized numerical control (CNC) milling machines. Established in 2015, CloudNC aims to modernize the manufacturing industry by creating advanced software that allows factories to autonomously produce precision parts, which are essential for various aspects of modern life, including automotive, aerospace, and electronics. The company's technology transforms CNC milling machines into user-friendly devices that require minimal human intervention, thus enhancing efficiency, reducing lead times, and increasing scalability for manufacturers. By focusing on automation and sustainability, CloudNC seeks to revolutionize the manufacturing process, making it ten times more efficient and positioning itself at the forefront of a $150 billion industry.

Proximie Inc. is a health technology company based in Bedford, Massachusetts, that specializes in a telehealth platform designed for virtual surgical assistance. Founded in 2016 by Nadine Hachach-Haram, Proximie's platform enables surgeons to remotely observe and guide complex surgical procedures using augmented reality, artificial intelligence, and machine learning. This technology allows expert surgeons to connect with their peers globally, sharing knowledge and skills in real-time, regardless of their physical location. The platform is adaptable, compatible with various devices and software used in operating rooms, and can function effectively even in low bandwidth environments. Proximie aims to enhance surgical practices by democratizing access to expert guidance and fostering collaboration among medical professionals.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Microbiotica Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. The company specializes in the development of human microbiome-based therapeutics and biomarkers. Its platform is designed to identify gut bacteria associated with specific phenotypes, offering a high level of precision. This capability allows researchers to determine phenotypes before conducting tests on candidate bacteria using advanced in vitro and in vivo models. By focusing on the science of the microbiome, Microbiotica aims to advance the understanding and application of live bacterial therapeutics in clinical settings.

Thought Machine is a fintech company focused on transforming core banking through innovative cloud-native technology. The company addresses the challenges posed by outdated IT infrastructure that many banks rely on, which hinders their capacity for innovation and customer service. Its primary product, Vault, is a comprehensive retail banking platform designed with a microservice API architecture that can be easily configured to meet the specific needs of various banks. By enabling banks to modernize their systems, improve user experiences, and enhance data analysis capabilities, Thought Machine aims to facilitate a significant evolution in the banking sector, fostering a more efficient and responsive financial environment.

Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.

Ultraleap Limited is a leading developer of mid-air haptic control systems and 3D hand tracking technology. Formerly known as Ultrahaptics, the company specializes in creating solutions that utilize ultrasound to generate tactile sensations, enabling users to feel three-dimensional shapes and textures without physical contact. Its flagship products include the Leap Motion Controller, which captures hand movements, and the VR Developer Mount, designed for enhancing virtual reality experiences on various headsets. The company's innovative technology is applicable across multiple industries such as extended reality, automotive, digital signage, industrial automation, consumer electronics, and location-based entertainment. Established in 2013 and headquartered in Bristol, United Kingdom, Ultraleap also has a subsidiary in Silicon Valley, United States.

AccuRx is a healthcare communication platform that facilitates seamless interaction between patients and healthcare professionals. The platform enables users to send SMS messages, conduct video consultations, manage appointment bookings, and distribute medical surveys. It also supports the organization of outpatient clinics, virtual wards, and follow-up pathways, enhancing the overall efficiency of primary care. With its adoption by 98% of GP practices and 50% of NHS trusts, AccuRx plays a crucial role in improving communication and collaboration in patient care, ensuring that all parties involved can connect easily and effectively.

Quantexa Limited is a global data and analytics software company based in London, United Kingdom, specializing in Contextual Decision Intelligence. Incorporated in 2016, Quantexa develops advanced entity resolution and network analytics technology that empowers organizations to improve their operational decisions by unifying siloed data and generating a comprehensive view of internal and external information. Its platform leverages artificial intelligence to uncover hidden risks and opportunities, providing critical insights into the relationships between individuals, organizations, and locations. Quantexa's solutions address challenges in areas such as fraud prevention, anti-money laundering, compliance, and customer insights, serving clients across financial services, corporate sectors, and public organizations worldwide. The company has established a strategic alliance with Accenture to enhance its offerings and expand its market reach.

Thought Machine is a fintech company focused on transforming core banking through innovative cloud-native technology. The company addresses the challenges posed by outdated IT infrastructure that many banks rely on, which hinders their capacity for innovation and customer service. Its primary product, Vault, is a comprehensive retail banking platform designed with a microservice API architecture that can be easily configured to meet the specific needs of various banks. By enabling banks to modernize their systems, improve user experiences, and enhance data analysis capabilities, Thought Machine aims to facilitate a significant evolution in the banking sector, fostering a more efficient and responsive financial environment.

Quantexa Limited is a global data and analytics software company based in London, United Kingdom, specializing in Contextual Decision Intelligence. Incorporated in 2016, Quantexa develops advanced entity resolution and network analytics technology that empowers organizations to improve their operational decisions by unifying siloed data and generating a comprehensive view of internal and external information. Its platform leverages artificial intelligence to uncover hidden risks and opportunities, providing critical insights into the relationships between individuals, organizations, and locations. Quantexa's solutions address challenges in areas such as fraud prevention, anti-money laundering, compliance, and customer insights, serving clients across financial services, corporate sectors, and public organizations worldwide. The company has established a strategic alliance with Accenture to enhance its offerings and expand its market reach.